Format

Send to

Choose Destination
Trop Med Int Health. 2018 Jun;23(6):641-649. doi: 10.1111/tmi.13065. Epub 2018 May 25.

Prevalence and risk factors for HBV and HCV in prisoners in Iran: a national bio-behavioural surveillance survey in 2015.

Author information

1
Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
2
Iranian Center for Communicable Diseases Control, Ministry of Health & Medical Education, Tehran, Iran.
3
Pasteur Institute of Iran, Tehran, Iran.
4
Health and Treatment Directorate of Prisons and Security and Corrective Measures Organization, Tehran, Iran.
5
Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
6
Iran University of Medical Sciences, Tehran, Iran.

Abstract

OBJECTIVES:

To provide more accurate estimates of the prevalence of Hepatitis B (HBV) and Hepatitis C (HCV) and their contributing factors among prisoners in Iran.

METHODS:

Cross-sectional study of 6200 Iranian prisoners in 2015. Data were collected through questionnaires and interviews. HBV infection and HCV exposure status of the participants was determined by HBsAg and HCV antibodies blood tests using enzyme-linked immunosorbent assay (ELISA). Data were analysed in STATA-12.

RESULT:

Prevalence of HCV exposure was 9.48% (95% CI: 8.73-10.27), and prevalence of HBV was 2.48% (95% CI: 2.07-2.89) in the general prison population. In multivariate analysis, the most important risk factor for HBV was a history of drug use in lifetime (adjusted odds ratio, AOR: 1.8, 95% CI: 1.17-3.02). The main risk factors for HCV exposure were a history of drug use in lifetime (AOR: 4.08, CI: 2.56-6.27), age over 30 (AOR: 2.68, CI: 2.01-3.56), and having tattoos (AOR = 1.67, CI: 1.35-2.07).

CONCLUSION:

Although vaccination is used to control HBV among prisoners, prevalence of HCV exposure is alarming in the prison population of Iran, especially among people who inject drugs. Eliminating viral hepatitis in Iran by 2030 requires a national commitment and rapid measures for targeting this high-risk group. Given the increased efficiency of HCV treatment in recent years, prisons provide an opportunity to access patients for treatment.

KEYWORDS:

VHB ; VHC ; Iran; Prevalence; drug user; hepatitis B virus; hepatitis C virus; prison; prévalence; toxicomanie

PMID:
29698576
DOI:
10.1111/tmi.13065

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center